Do the MEFV gene mutations increase in patients with autosomal dominant polycystic kidney disease? Preliminary analysis

MEFV gene mutation and autosomal dominant polycystic kidney disease

Ismail Dogan1, Alpaslan Altunoglu1, Cemaleddin Ozturk1, Kubra Kose1, Gokhan Yuce5, Osman Ersoy6, Sukran Erten1

1 Department of Rheumatology, Yildirim Beyazit University Faculty of Medicine, 2 Department of Nephrology, Ankara City Hospital, 3 Department of Hematology, Ankara University School of Medicine, 4 Yildirim Beyazit University Faculty of Medicine, 5 Ankara City Hospital, Department of Radiology, 6 Yildirim Beyazit University Faculty of Medicine, Ankara City Hospital, Department of Gastroenterology, Ankara, Turkey

Abstract

Aim: The aim of the present study was to evaluate the frequency of MEFV gene mutations in autosomal dominant polycystic kidney disease (ADPKD) patients with abdominal pain, tenderness, fever or arthritis attacks who may have coexistence of Familial Mediterranean Fever (FMF).

Materials and Methods: Twenty-five ADPKD patients with the medical history of recurring and self-limited episodes of fever, abdominal pain, and inflammatory arthritis of one or several serous (peritoneum, pleura, pericardium, synovial or vaginal tunic of the testicle) membranes attending consecutively our nephrology, rheumatology, and gastroenterology departments were included in the study, and MEFV gene mutations were analyzed.

Results: In this study, twenty-five ADPKD patients (male/female: 15/10) were included. The mean age was 43.8 years. In 8 ADPKD patients, MEFV gene mutations were determined with 9 allelic variants. We found the prevalence of total allelic MEFV variants to be the same in ADPKD patients (32%) compared with healthy Turkish subjects (p > 0.05). According to the Tel-Hashomer criteria, four patients with proteinuria higher than 1000 mg were diagnosed with FMF and amyloidosis by endoscopic biopsies.

Discussion: Coexistence of two common genetic and systemic disorders like ADPKD and FMF may take place. Furthermore, MEFV gene mutations may play a role in the development of FMF-related amyloidosis in ADPKD patients. Colchicine use in FMF, besides preventing the development of amyloidosis, may also prevent the development of cysts in the concurrence with ADPKD. Further large clinical studies on this subject are needed.

Keywords

Autosomal Dominant Polycystic Kidney Disease; Familial Mediterranean Fever; MEFV Gene Mutation; Colchicine; Amyloidosis

DOI: 10.4328/ACAM.20053  Received: 2019-08-30 Accepted: 2019-10-19 Published Online: 2019-10-20  Printed: 2020-07-01 Ann Clin Anal Med 2020;11(4):311-313

Corresponding Author: Ismail DOĞAN, MD, Instructor in Internal Medicine and Rheumatology, Yildirim Beyazit University Faculty of Medicine, Bilkent, Ankara, Turkey.
E-mail: dridogan@hotmail.com  Tel:+90 312 552 60 00  Corresponding Author ORCID ID: https://orcid.org/0000-0002-7963-9484
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the inherited renal cystic diseases resulting in a high ratio of the end-stage renal disease (ESRD) in the Turkish population [1]. Familial Mediterranean fever (FMF) is an autosomal recessive systemic autoinflammatory disease characterized by recurrent attacks of polyserositis and fever [2]. ADPKD is one of the most frequent inherited kidney disease, with a prevalence of 1/1000 [3], caused by polycystins 1 and 2, PKD1 and PKD2 gene mutations in 85% and 15% of the cases respectively [4].

PKD1 gene of ADPKD and MEFV gene are located on the same chromosome region (16p13.3), but slightly differently placed on 46 exons and 2, 10 exons respectively [4,5]. Fever and abdominal pain/tenderness in ADPKD patients are generally believed to have resulted from the renal and urinary complications. However, these symptoms also may be caused by inflammation of serous membranes due to FMF. These individuals with ADPKD may have increased frequency of MEFV gene mutation in risk groups. Therefore, we aimed to evaluate the frequency of MEFV gene mutations in ADPKD patients with abdominal pain, tenderness, fever or arthritis attacks who may have coexistence of FMF.

Material and Methods
Twenty-five ADPKD patients with the medical history of recurrent and self-limited episodes of fever, abdominal pain and inflammatory arthritis of one or several serous membranes attending consecutively our nephrology, rheumatology, and gastroenterology departments were recruited into the study. Informed consent was obtained from all individual participants included in the study. In enrolled patients, the diagnosis of ADPKD was re-established based on family history (family anamnesis), clinical data, and a new ultrasound of kidneys using the criteria described by Pei et al. [6]. Unfortunately, no additional genetic profiling was performed in ADPKD patients and MEFV gene mutations were analyzed. DNA was extracted from peripheral blood leukocytes using standard protocols (Invisorb® Spin Blood Kit, STRATEC Molecular GmbH, D-13125; Berlin, Germany). Molecular analyses were performed within the framework of routine genetic testing. The presence of MEFV mutation was investigated in exons 2, 3, 5 and 10 by the multiplex-PCR reverse hybridization method. Familial Mediterranean fever was diagnosed on the basis of the Tel-Hashomer diagnostic criteria [7]. The diagnosis of amyloidosis was based on histological proof of congophilic fibrillar deposits in endoscopic biopsy specimens.

Statistical analyses
Statistical analysis was performed using the Statistical Package for Social Science (SPSS) software, version 15.0 statistical package program (IBM Inc.; Chicago, IL, USA). Demographic and clinical variables were summarized as proportions. The Chi-square test was used for the comparison of categorical variables. A p-value <0.05 was considered as statistically significant.

Results
In this study, twenty-five ADPKD patients (male/female:15/10) were included. The mean age was 43.8 years. In 8 ADPKD patients, MEFV gene mutations were determined with 9 allelic variants. The allelic variants were heterozygous for M694V (4/50, 8%), E148Q (2/50, 4%), V726A, P369S, A744S, and compound heterozygous for M680I/M694V. According to the Tel-Hashomer criteria, four patients with proteinuria higher than 1000 mg were diagnosed with FMF and amyloidosis by endoscopic biopsies. Two of them were heterozygous for M694V, one of them was heterozygous for A744S, and one of them was compound heterozygous for M680I / M694V. Two of the 4 patients with ESRD and amyloidosis (M694V and A744S) had a successful living and cadaveric donor renal transplantations after a 5-year dialysis period at the age of 48, 59 years, respectively.

Discussion
In the current study, we found that the prevalence of total allelic MEFV variants tends to be high in ADPKD patients (32%) compared with healthy Turkish subjects (p > 0.05). In the literature, a high frequency of MEFV carriers in a healthy Turkish population (20%) was reported [8].

In ADPKD and FMF, the genetic mutations are present in the same chromosome region, suggesting that these two diseases would occur together [4,5]. Özen et al. pointed out the prevalence of FMF (included Turkish patients) among four ethnic groups as high as 1/500 in a ratio which is alike to the prevalence of 1/1000 in ADPKD patients [3,9].

As a result of the disorder occurring in the synthesis of pyrin due to the MEFV gene mutation, the increase of acute inflammation can contribute to the concurrence of inflammatory diseases other than FMF. Earlier studies have reported increased frequency of Henoch-Schonlein purpura, polyarteritis nodosa, ankylosing spondylitis, Behcet disease, and inflammatory bowel diseases in FMF patients [10-11,12]. In those with negative MEFV gene mutation FMF patients, the absence of other concurrent autoimmune diseases may indicate the role of MEFV gene mutation [12].

Although there was no statistically significant increase in MEFV gene mutations in ADPKD patients compared with the healthy controls in the Turkish population, four patients were diagnosed with FMF and amyloidosis according to the Tel-Hashomer diagnostic criteria [7].

In ADPKD, usually moderate proteinuria may be seen in conjunction with renal failure, but the development of proteinuria and amyloidosis in nephrotic level is rare. The most important reason for the development of amyloidosis is chronic cyst infection [13,14].

The ADPKD phenotype displays a significant variability that is widely influenced by the affected gene. In PKD1 patients, a median age at onset of ESRD was 58 years [4], and about 2–5% of ADPKD patients present with an early and severe phenotype [15]. There may be a coexistence of these two common genetic disorders. Although it is not certain, amyloidosis in these cases may take place due to FMF or recurrent cyst infections. MEFV
gene mutations here may play a role in the development of FMF-related amyloidosis in ADPKD patients.

In this regard, MEFV gene mutations, comorbidities, and/or other urological, renal complications (like amyloidosis) may constitute the severity and early manifestation of ADPKD. Colchicine is an effective drug used in the treatment of FMF to prevent the development of attacks and amyloidosis. Colchicine is a microtubule inhibitor, preventing cell migration, division, and polarisation. It also has anti-apoptotic, anti-proliferative and anti-inflammatory effects [16]. Many of the effects of colchicine have pathophysiological counterpart of ADPKD, thus Solak et al. hypothesized that colchicine would be beneficial for regression and/or prevention of cyst formation in ADPKD [16]. Our study constitutes another basis for the use of colchicine in patients with ADPKD which in addition to preventing the development of cysts, may also prevent the development of amyloidosis especially in the presence of FMF.

As a conclusion, ADPKD patients may have similar symptoms with FMF like fever, tenderness, abdominal pain, loss of appetite, nausea and vomiting. In regions and ethnic groups where FMF prevalence is high, FMF symptoms and ADPKD complications should be differentiated. Further large clinical trials are necessary to evaluate whether the coexistence of these two disorders can simply be explained as incidental or not. The clinical therapeutic effect of colchicine on cyst development in patients with ADPKD should be investigated.

Limitations of the study
A number of limitations of the study design should be acknowledged and kept in mind when evaluating the consequences. First, we did not analyze the molecular genotyping of the included participants and thus have no way to determine whether PKD1, PKD2 and/or even overlap undetermined mutations caused the genotype-phenotype correlations in ADPKD patients. Secondly, data sets of a small number of patients (there were only 25 individuals) were limited to assess the results. Finally, the etiology of amyloidosis may not certainly be determined if it is due to FMF or chronic cyst infections.

Scientific Responsibility Statement
The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

Funding: None

Conflict of interest
None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

References
1. Kocyiğit I, Yılmaz MI, Gungor O, Erolgu E, Unal A, Orsçelik O, et al. Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease. BMC Nephrol. 2016;17(1):196.
2. Altunaoğlu A, Ertan Ş, Canöz MB, Yokuşal A, Ceylan GC, Balıç S, et al. Phenotype 2 familial Mediterranean fever: evaluation of 22 case series and review of the literature on phenotype 2 FMF. Ren Fail. 2013;35(2):226-30.
3. Ozen S, Batu ED. The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol. 2015;37(4):363-9.
4. Trujillano D, Ballich G, Ossowski S, Ballaran J, Torra R, Estivill X, et al. Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing. Mol Genet Genomic Med. 2014;2(5):412-21.
5. Cetin D, Genç Çetin B, Sentürk T, Sahin Çiğdem S, Yılmaz Akdem I. Coexistence of two rare genetic disorders: Kartagener syndrome and familial Mediterranean fever. Mod Rheumatol. 2015;25(2). DOI: 10.3109/14397595.2013.874756.
6. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dickens E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-12.
7. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lind T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879-85.
8. Yılmaz E, Ozen S, Balıç B, Duruva A, Topaloglu R, Besbas N, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high Carrier rate in the Turkish population. Eur J Hum Genet. 2001; 9 (7): 553-5.
9. Mallowaanachichi AC, Furlong TJ, Shine J, Harris PC, Cowley MJ. Population data improves variant interpretation in autosomal dominant polycystic kidney disease. Genet Med. 2019; 21(6):1425-34.
10. Korkmaz C, Özdoğan H, Kasapçopur O, Yazıcı H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002;61:79-88.
11. Özdoğan H, Artiso N, Kasapçopur O, Sever L, Çalışkan S, Tuzuner N, et al. Vasculitis in familial Mediterranean fever. J Rheumatol. 1997;24: 323-7.
12. Gancan S, Bilge N Ş, Cansu DÜ, Kasföğülu T, Korkmaz C. The role of MEFV mutations in the concurrent disorders observed in patients with Familial Mediterranean fever. Eur J Rheumatol. 2016;3 (3):116-21.
13. Venigun EC, Dedê F, Ozkaya N, Turgut D, Piskinpasas SV, Oztruk R, et al. Coexistence of autosomal dominant polycystic kidney disease and amyloidosis in a patient with nephrotic-range proteinuria. Iran J Kidney Dis. 2014;8(3):243-5.
14. Tsuchiya Y, Ukara Y, Suwabe T, Nomura K, Sumida K, Hiramatsumi R, et al. Amyloidosis in autosomal dominant polycystic kidney disease caused by chronic cyst infections lasting for 30 years. Intern Med. 2013;52(7):791-4.
15. Eisenberger T, Decke C, Hiersche M, Hamann RC, Decke E, Neuber S, et al. An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease. PLoS One. 2015;3;10(2). DOI: 10.1371/journal.pone.0116680.
16. Solak Y, Atalay H, Polat İ, Biyik Z. Colchicine treatment in autosomal dominant polycystic kidney disease: many points in common. Med Hypotheses. 2010;74(2):314-17.

How to cite this article:
İsmail Dogan, Alpaslan Altunoğlu, Cemaleddin Ozturk, Kubra Kose, Gokhan Yuce, Osman Ensoy, Sukran Ertan. Do the MEFV gene mutations increase in patients with autosomal dominant polycystic kidney disease? Preliminary analysis. Ann Clin Anal Med. 2020;11(4):311-313.